ALK and non-small cell lung carcinoma: Labarca and colleagues recently performed a meta-analysis examining the adequacy of tissue sampling via EBUS-TBNA for molecular prognostication in cases of commonly reported NSCLC mutations, such as EGFR, ALK, and PD-L1.